[go: up one dir, main page]

EA199900907A1 - 4,4-DESIGNED 3,4-DIHYDRO-2 (1H) -CHINAZOLINONES USEFUL AS HIV REVERSE TRANSPRIPTASE INHIBITORS - Google Patents

4,4-DESIGNED 3,4-DIHYDRO-2 (1H) -CHINAZOLINONES USEFUL AS HIV REVERSE TRANSPRIPTASE INHIBITORS

Info

Publication number
EA199900907A1
EA199900907A1 EA199900907A EA199900907A EA199900907A1 EA 199900907 A1 EA199900907 A1 EA 199900907A1 EA 199900907 A EA199900907 A EA 199900907A EA 199900907 A EA199900907 A EA 199900907A EA 199900907 A1 EA199900907 A1 EA 199900907A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydro
inhibitors
useful
hiv reverse
transpriptase
Prior art date
Application number
EA199900907A
Other languages
Russian (ru)
Other versions
EA001991B1 (en
Inventor
Джеффри В. Корбетт
Соо Сунг Ко
Original Assignee
Дюпон Фармасьютикалз Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дюпон Фармасьютикалз Компани filed Critical Дюпон Фармасьютикалз Компани
Publication of EA199900907A1 publication Critical patent/EA199900907A1/en
Publication of EA001991B1 publication Critical patent/EA001991B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к 4,4-дизамещенным 3,4-дигидро-2(1Н)-хиназолинонам формулы (I)или их стереоизомерным формам, смесям стереомерных форм или их фармацевтически приемлемым солям, которые полезны в качестве ингибиторов обратной транскриптазы ВИЧ, и к их фармацевтическим композициям и диагностическим наборам, содержащим их, и способам применения их для лечения вирусной инфекции или в качестве тест-стандарта или реагента.Отчет о международном поиске опубликован 1999.01.14.The present invention relates to 4,4-disubstituted 3,4-dihydro-2 (1H) -quinazolinones of formula (I) or their stereoisomeric forms, mixtures of stereomeric forms or their pharmaceutically acceptable salts, which are useful as inhibitors of HIV reverse transcriptase, and their pharmaceutical compositions and diagnostic kits containing them, and methods for using them to treat a viral infection or as a test standard or reagent. An international search report published 1999.01.14.

EA199900907A 1997-04-09 1998-04-07 4,4-disubstituted -3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitots EA001991B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
EA199900907A1 true EA199900907A1 (en) 2000-04-24
EA001991B1 EA001991B1 (en) 2001-10-22

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900907A EA001991B1 (en) 1997-04-09 1998-04-07 4,4-disubstituted -3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitots

Country Status (19)

Country Link
EP (1) EP0973753A2 (en)
JP (1) JP2002504095A (en)
KR (1) KR20010006146A (en)
CN (1) CN1252063A (en)
AR (1) AR012340A1 (en)
AU (1) AU734928B2 (en)
BR (1) BR9808513A (en)
CA (1) CA2284996A1 (en)
EA (1) EA001991B1 (en)
EE (1) EE9900452A (en)
HR (1) HRP980143A2 (en)
HU (1) HUP0001446A3 (en)
IL (1) IL132188A0 (en)
NO (1) NO314936B1 (en)
NZ (1) NZ500592A (en)
PL (1) PL336305A1 (en)
SK (1) SK137899A3 (en)
TW (1) TW587078B (en)
WO (1) WO1998045276A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068189A1 (en) * 1998-03-27 2001-01-17 Bristol-Myers Squibb Pharma Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
WO2000029390A1 (en) * 1998-11-19 2000-05-25 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1268447A2 (en) * 2000-03-23 2003-01-02 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
US6555686B2 (en) 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
JP2006514045A (en) * 2002-12-16 2006-04-27 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Treatment of HIV infection by combined administration of tipranavir and capravirin
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR AN IMPROVED SAMPLING INTERFERENCE DEVICE
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND DEVICE FOR A VARIABLE USER INTERFACE
WO2005065414A2 (en) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (en) * 2011-01-20 2011-05-18 天津大学 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof
CA2832022C (en) * 2011-04-06 2019-01-08 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
JP6171003B2 (en) 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP3004109A1 (en) 2013-05-27 2016-04-13 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
MX2015016425A (en) 2013-05-28 2016-03-03 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
JP2016520118A (en) 2013-05-28 2016-07-11 ノバルティス アーゲー Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of diseases
CA2931249A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN116745269A (en) * 2020-08-27 2023-09-12 默沙东有限责任公司 Dihydroquinazolin-2-one derivatives as selective cytotoxic agents for the treatment of HIV
WO2025014788A1 (en) * 2023-07-07 2025-01-16 Merck Sharp & Dohme Llc Tetrahydroquinazoline derivatives as selective cytotoxic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (en) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazoline derivatives and medicaments containing them
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
AR012340A1 (en) 2000-10-18
CA2284996A1 (en) 1998-10-15
EP0973753A2 (en) 2000-01-26
AU734928B2 (en) 2001-06-28
NZ500592A (en) 2001-09-28
NO994904D0 (en) 1999-10-08
KR20010006146A (en) 2001-01-26
NO314936B1 (en) 2003-06-16
AU6796098A (en) 1998-10-30
HUP0001446A3 (en) 2001-11-28
WO1998045276A3 (en) 1999-01-14
EA001991B1 (en) 2001-10-22
NO994904L (en) 1999-12-01
HUP0001446A2 (en) 2001-05-28
SK137899A3 (en) 2000-05-16
EE9900452A (en) 2000-04-17
PL336305A1 (en) 2000-06-19
JP2002504095A (en) 2002-02-05
WO1998045276A2 (en) 1998-10-15
BR9808513A (en) 2000-05-23
CN1252063A (en) 2000-05-03
HRP980143A2 (en) 1999-02-28
TW587078B (en) 2004-05-11
IL132188A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
EA199900907A1 (en) 4,4-DESIGNED 3,4-DIHYDRO-2 (1H) -CHINAZOLINONES USEFUL AS HIV REVERSE TRANSPRIPTASE INHIBITORS
EA200200471A1 (en) CONDENSED NAFTYRIDINES AS HIV Reverse Transcriptase Inhibitors
AU4802797A (en) 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv rever se transcriptase inhibitors and intermediates and processes for making the same
DK1040108T3 (en) Orthoanthranilamide derivatives as anticoagulants
EA200400023A1 (en) HIV PROTEASE INHIBITORS, CONTAINING THEIR COMPOSITIONS, THEIR PHARMACEUTICAL USE AND MATERIALS FOR THEIR SYNTHESIS
ATE273305T1 (en) THROMBIN INHIBITORS
EA199900746A1 (en) DESIGNED BICYCLIC HETEROCYCLES, THEIR OBTAINING AND APPLICATION AS A MEDICINE
EA199800752A1 (en) PENTAFTORBENZOLSULPHONAMIDES AND THEIR ANALOGUES
ATE211732T1 (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
EA200200774A1 (en) NEW CONNECTIONS, HAVING HYPOLIPIDEMIC, HYPOCHOLESTERYNAMIC ACTIVITY, METHOD OF THEIR PREPARATION AND CONTAINING THEIR COMPOSITION
WO2004002410A3 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
MD1560G2 (en) Cyclic compounds, pharmaceutical compositions based on them and methods for treating infections or diseases caused by retroviruses
EA200400690A1 (en) NUCLEOSIDES, THEIR PREPARATIONS AND THEIR APPLICATION AS VIRAL RNA POLYMERASE INHIBITORS
BR9712707A (en) Derivatives of 4-biphenyl-4-hydroxybutyric acid replaced with matrix metalloprotease inhibitors
YU62504A (en) Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors
EA199800661A1 (en) Aspartic protease inhibitors
EA200400806A1 (en) METHOD OF OBTAINING ECHINOCANDINE COMPOUNDS
YU3203A (en) Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
EA200300400A1 (en) 17α-FLUORALKYLSTEROIDS, METHOD FOR THEIR PRODUCTION, AND CONTAINING THESE COMPOUNDS PHARMACEUTICAL COMPOSITIONS
EA199900452A1 (en) 1- (3-AMINOINDAZOL-5-IL) -3-PHENILMETHYL CYCLIC URECHANES, USEFUL AS HIV-PROTEASE INHIBITORS
EA200500287A1 (en) 4- (3, 5-ditsianofenoksi) derivatives of pyrazole for use as reverse transcriptase modulators in treatment, including, for example, HIV infection
EA199900451A1 (en) (4R, 5S, 6S, 7R) -HEXAHYDRO-1- [5- (3-AMINOINDAZOL) METHYL] -3-BUTYL-5,6-DIHYDROXI-4,7-BIS [Phenylmethyl] -2H-1,3- DIAZEPIN-2-IT, ITS OBTAINING AND ITS APPLICATION AS AN HIV PROTEASE INHIBITOR
WO2000073284A3 (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
WO2002078628A3 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazapines as hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU